STOCKSCREENR

NVO

NYSE

Novo Nordisk A/S

$42.22+1.93(+4.79%)Mkt Cap: $187.63B

Key Stats

Market Cap

$187.63B

P/E Ratio

11.70

EPS

$3.61

Dividend Yield

4.41%

52-Week Range

$35.12 — $81.44

Volume

25.07M

Avg Volume

22.17M

Beta

0.27

Price Alerts for NVO

Get alerted when NVO hits your target price.

$

Free — enter your email to get started

Valuation

P/E (TTM)

11.70

Forward P/E

1.98

PEG Ratio

6.86

P/S (TTM)

3.81

P/B (TTM)

6.07

P/FCF

-133.70

EV/EBITDA

43.17x

EV/Sales

—

Financial Health

ROE (TTM)

0.61%

ROA (TTM)

0.19%

ROIC

0.10%

Gross Margin

0.81%

Operating Margin

0.41%

Net Margin

0.34%

Debt/Equity

0.67

Current Ratio

0.80

Growth

EPS Growth (YoY)

-0.05%

Revenue Growth (YoY)

-0.07%

EPS Growth (3Y)

+0.25%

EPS Growth (5Y)

+0.22%

Sales Growth (3Y)

+0.20%

Sales Growth (5Y)

+0.19%

EPS Est (This Year)

$21.31

EPS Est (Next Year)

$21.62

Dividends

Dividend Yield

—

Annual Dividend

$0.41

Payout Ratio

0.00%

Frequency

—

Ex-Dividend Date

2025-08-18

Cash/Share

$6.07

Analyst Consensus

2.0

Buy

1 = Strong Buy, 5 = Strong Sell

Price Target Range

$42.00$45.00$54.00
LowMedianHigh

Consensus Target: $47.00(11.3% upside)

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

—

Outstanding Shares

4.44B

Float

3.19B

Free Float %

71.74%

Technicals

RSI (14)

32.56

SMA 20

$56.72

SMA 50

$53.26

SMA 200

$57.08

ATR (14)

3.00

Volatility (Week)

0.09%

Volatility (Month)

0.05%

Pattern

—

Performance

1 Day

-0.51%

1 Week

-2.35%

1 Month

-16.48%

3 Months

+7.53%

6 Months

-1.50%

1 Year

—

YTD

-6.24%

All-Time High

$93.80

About

Sector

Healthcare

Industry

Drug Manufacturers - General

Country

DK

Exchange

NYSE

IPO Date

1981-04-30

Employees

77406

CEO

Maziar Mike Doustdar

Index Membership

—

Website

https://www.novonordisk.com

Novo Nordisk A/S (NVO) is a healthcare company in the drug manufacturers - general industry listed on the NYSE. With a market capitalization of $187.63B, a P/E ratio of 11.70, and a dividend yield of 4.41%, NVO is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare NVO against other stocks using dozens of fundamental and technical filters.

Similar Stocks

AZN

AstraZeneca PLC

$187.37

+1.17%

$290.48B

MRK

Merck & Co., Inc.

$109.15

-1.62%

$269.59B

JNJ

Johnson & Johnson

$229.85

+1.10%

$553.30B

PFE

Pfizer Inc.

$26.70

+1.68%

$151.88B

ABBV

AbbVie Inc.

$211.33

+3.65%

$373.79B

BMY

Bristol-Myers Squibb Company

$60.59

+5.21%

$123.71B

Frequently Asked Questions

What is Novo Nordisk A/S's P/E ratio?

Novo Nordisk A/S (NVO) has a trailing twelve-month (TTM) P/E ratio of 11.70. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Novo Nordisk A/S pay a dividend?

No, Novo Nordisk A/S (NVO) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Novo Nordisk A/S's market cap?

Novo Nordisk A/S (NVO) has a market capitalization of $187.63 billion, classifying it as a large-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.

What do analysts think about NVO?

Wall Street analysts have a consensus "Buy" rating on Novo Nordisk A/S (NVO) with an average score of 2.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $47.00 implies 11.3% upside from the current price.

How has NVO performed this year?

Novo Nordisk A/S (NVO) has returned -6.24% year-to-date. Past performance does not guarantee future results, but these figures reflect the stock's recent price trajectory relative to the broader market.